Uloric Drug Safety Update: A Significantly Higher Risk Of Death Among Patients Using Gout Drug Uloric As Opposed To Allopurinol

Recent Findings Come From The CARES Trial, A Postmarketing Safety Study Requested By FDA Back When Uloric Was Approved In 2009   (Posted by Tom Lamb at DrugInjuryWatch.com)   At the recent American College of Cardiology (ACC) 2018 Annual Scientific Session meeting, the gout drug Uloric (febuxostat) was the subject of some safety concerns and some uncertainty due to findings of higher risk of death when compared to an alternative gout treatment drug, allopurinol, but the mechanism behind this difference is not readily apparent. Allopurinol, approved by the FDA in 1966, and Uloric, approved in 2009, are the two commonly prescribed preventive medicines for gout. Takeda Pharmaceuticals is the drug company responsible for Uloric. The findings presented at this 2018 ACC meeting came from the Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Comorbidities (CARES) trial, or drug study, sponsored by Takeda Pharmaceuticals as an FDA…

Read more detail on Recent Health Care Law posts –

This entry was posted in Health Law and tagged , , , , , , , , , , , , , . Bookmark the permalink.

Leave a Reply